The Dietary Supplement and Prescription Medication section of the Sample Person (SP) Questionnaire collects information on: 1) dietary supplements, 2) nonprescription antacids, 3) prescription medications, and 4) preventive aspirin use.
The Prescription Medications subsection provides personal interview data on use of prescription medications during a one-month period prior to the participant’s interview date. The NHANES 2013–2014 prescription medication questions are similar to the NHANES 1999–2012 and NHANES III (1988–1994) prescription medication questions.
All survey participants are eligible for the prescription medications questions.
The Prescription Medications subsection was asked, in the home, by trained interviewers using the Computer-Assisted Personal Interview (CAPI) system. Participants over 16 years of age answered for themselves; a proxy provided information for survey participants who were under 16 years of age and for those who could not answer themselves.
The Interviewer Procedure Manuals and Survey Questionnaires can be found on the NHANES website at: https://wwwn.cdc.gov/nchs/data/nhanes/2013-2014/questionnaires/dsq_h.pdf.
Data were routinely examined for discrepancies and erroneous entries. All drug names entered by the interviewer were compared to the medication names selected from the database. Review of the 2013–2014 data found that 96% of all reported drugs were automatically matched to the data collection drug database. This included 81% exact matches, and 15% similar matches. All similar matched drug names were reviewed and edited if selected drug names from the database were incorrect. The 4%, which were not matched to the drug database, were edited after data collection at NCHS. The most common reasons for a non-match were incorrect spelling of the drug, insufficient detail to identify the drug, or reporting of a nonprescription product that was not in the drug database.
Beginning the 2013–2014, a list of possible reasons for use assigned to each drug was incorporated into the computer to assist data collection. Review of the 2013–2014 data found that 88% of all reported reasons were selected from the list. The 12%, which were entered in the reason filed, were edited after data collection at NCHS.
Data Collection Methods
During the household SP interview, survey participants are asked if they have taken medications in the past 30 days for which they needed a prescription. Those who answer “yes” are asked to show the interviewer the medication containers of all the products used. For each medication reported, the interviewer enters the product’s complete name from the container into a computer. If no container is available, the interviewer asks the participant to verbally report the name of the medication.
When the interviewer enters the medication name into the computer, the name is automatically matched to a prescription drug database on the computer to identify an exact match or similar text matches (refer below for details on the prescription medication database). The interviewer then selects the best match from a drug list of possible matches. The original product entered by the interviewer and the product selected from the computer drug list are saved as separate variables for quality control purposes. If an exact or similar match of the medication cannot be found, the interviewer is instructed to select “drug not found on list.”
Participants are also asked how long they had been taking the medication and the main reason for use. A list of possible reasons (indications of medication use and possible off-label use) pre-assigned to each selected drug is displayed on the computer. The interviewer is instructed to select up to 3 reasons from the reason list which are matching to the main reason described by the participant. If an appropriate matched reason cannot be found, the interviewer is instructed to enter the main reason as described by the participant.
The NHANES 2013–2014 prescription medications questions can be accessed in the Dietary Supplements and Prescription Medications section of the SP Questionnaire https://wwwn.cdc.gov/nchs/data/nhanes/2013-2014/questionnaires/dsq_h.pdf.
Prescription Medication Questions Included in this Data Release
Prescription Medication Database for Data Collection
NCHS used the Lexicon Plus®, a proprietary database of Cerner Multum, Inc. to assist in data collection. The Lexicon Plus® is a comprehensive database of all prescription and some nonprescription drug products available in the U.S. drug market. For NHANES, the Lexicon Plus® files were modified and uploaded to a laptop computer and incorporated into a search engine for use by interviewers in the field. The computer file is updated at the beginning of each survey year to incorporate changes to the Lexicon Plus® and include products approved and available to the U.S. public in the prior year.
Data Editing
General editing of data:
When a variable was modified globally, as part of the editing process, the third letter in the variable name was changed from a Q (i.e., RXQ) to a D (i.e., RXD). For example, variables that were obtained from an external drug database will have the letter “D” in the third position of the variable name.
Prescription medications incorrectly reported in other subsections of questionnaire:
Prescription antacids that were incorrectly reported in the nonprescription antacid section of the questionnaire were removed from the antacid file and added to the prescription medication file.
Prescription supplements are released in the Dietary Supplements Data File. Some prescription medications were mistakenly recorded in the dietary supplement section. These were removed from that file and added to the prescription medication file. Any prescription dietary supplement that was incorrectly reported in the prescription medication section was removed from the prescription medication section and moved to the dietary supplement section. The following products were moved to the dietary supplements files:
All prescription niacin, fish oil, potassium, and sodium products were retained in the prescription medication file.
Products reported in the prescription medication section that were only available as an over-the-counter product during 2013–2014 were removed from the prescription medication file, except over-the-counter insulin, and products containing pseudoephedrine.
Specific variables and edits:
RXDUSE: Have you taken or used any prescription medicines in the past month?
This variable was the lead-in question to the series of questions on prescription medication use. It accounts for all prescription medications except prescription dietary supplements which are included in the dietary supplement files (DSQ). A small number of persons refused to answer this question (coded 7) or did not know whether they used a prescription medication in the past month (coded 9).
This variable was edited and takes into account prescription medications reported in this section as well as prescription medications moved into this file from the dietary supplements or nonprescription antacids sections of the questionnaire.
RXDCOUNT: The number of prescription medicines taken?
This variable was computed at NCHS and represents the total number of prescription medications reported by the participant, including those drugs identified as unknown (RXDDRUG = 55555). The count has been adjusted for all prescription medications moved into and those moved out of the prescription medication section. However, the count is not a comprehensive count of all prescription medications used by a participant because prescription dietary supplements are part of the dietary supplement section. There were also participants who reported the use of a prescription medication in the past month (RXDUSE = 1) but did not know the name of the medication (RXDDRUG = 99999) or refused to report the name of the medication (RXDDRUG = 77777). Each product reported as “refused” or “don’t know” is still included in the total count of prescription medications used under RXDCOUNT.
RXQSEEN: Medicine container seen by interviewer?
There was no editing of this variable. However a third response category (3=Only pharmacy print out seen) was added beginning in the 2013–2014 data collection.
RXDDAYS: For how long have you been taking this medicine?
This variable was created from a two-part (number and unit) question and indicates how long the participant reported taking each prescription medication. Responses were recorded in days, weeks, months, and years. To facilitate analysis, all answers were converted to days using conversion factors of 7 days per week, 30.4 days per month, and 365 days per year. There were persons who reported the use of a prescription medication but did not know how long they had been using the medication (RXDDAYS = 99999) or refused to report the length of use (RXDDAYS = 77777). There were also persons who reported the use of a prescription medication but did not report the length of use. RXDDAYS is missing for those persons.
Drug Database for Data Release:
NCHS used the Lexicon Plus®, a proprietary database of Cerner Multum, Inc. to assist with data editing and release. The December 2014 Multum Lexicon database was used for creating the RXQ_RX_H data release file. For additional information, refer to the RXQ_DRUG documentation.
In accordance with the license agreement, NCHS publications, tabulations, and software applications should cite the Multum Lexicon as the source and basis for the coding and classification of the NHANES drCreation of additional data release variables:
Creation of additional data release variables:
RXDDRUG: Generic drug name
All reported drug names were converted to a standard generic drug name for data release. For multi-ingredient products, the ingredients are listed in alphabetical order (i.e., Acetaminophen; Codeine).
There were participants who reported the use of a prescription medication but did not know the name of the drug or refused to report the name. These entries were coded as don’t know (99999) and refused (77777), respectively. There were also medications reported with insufficient detail to accurately identify the exact product, but there was some information about the therapeutic class of the drug. These products have been released with Multum’s therapeutic category name followed by “- unspecified” (e.g., anti-infective - unspecified; hormones/hormone modifiers - unspecified). The names of a limited number of reported drugs could not be identified by NCHS as a known prescription product. These entries are counted as prescription medications, since there is no evidence that they are not, and have been coded as 55555, unknown drug.
RXDDRGID: Generic drug code
Each generic drug name is associated with a unique generic drug code from Multum’s Lexicon Drug Database. Multum's generic drug code is always beginning with a "d". There were some drug names reported by NHANES’ participants that were not found in the Lexicon Drug Database. These have been assigned unique drug codes beginning with an “a” or “h”. Unspecified products with known therapeutic action have drug codes beginning with a “c” and are followed by their respective Multum therapeutic category code. RXDDRGID is missing for unknown drugs (55555), refused (77777), or don’t know (99999) RXDDRUG entries.
Therapeutic class codes associated with a drug are found in a separate data release file, RXQ_DRUG.
International Classification of Disease, Tenth Revision, Clinical Modification (ICD-10-CM) Code for Data release
To facilitate data analysis, NCHS used ICD-10-CM codes to classify the health problems participants reported as the main reason for taking the prescription medication. Thus, the associated ICD-10-CM codes are based on participant reported reason and not directly reported by a doctor or other health professional or by a review of the medical record. Specifically, 2016 ICD-10-CM codes from ICD-10 data (http://www.icd10data.com/ICD10CM/Codes) were used to assign up to a maximum of 3 codes. ICD-10 diagnosis codes have between 3 and 7 characters. In general, the self-reported health problems were coded to the fourth digit ICD-10-CM level of specificity. However, in some cases only the first three digits as the heading of a category of codes was used, and in other cases the six digits ICD-10-CM level of specificity was used. See the Appendix for a list of ICD-10-CM codes and description assigned to reasons for use reported by NHANES participants.
Reason for use (as reported by participant) data release variables:
RXDRSC1-- RXDRSC3: ICD-10-CM code
The participants’ reported reasons were converted to an ICD-10-CM code for data release. Up to a maximum of 3 ICD-10-CM codes were used if multiple reasons were reported for a specific medication use. When reported reason was for disease prevention, an appropriate ICD-10-CM code followed by a letter "P" was used. (e.g., A49.9P Prevent bacterial infection; D75.9P Prevent blood clots). When reported reason was not specifically enough to be assigned an ICD-10-CM code for the subtype of disease, an ICD-10-CM code for a most common subtype of disease was used. (e.g., B19.1 for hepatitis B; E11 for diabetes; E78.0 for high cholesterol). When reported reason did not indicate a single episode or recurrent, an ICD-10-CM code for a single episode was used (e.g., F32.9 for depression). When reported reason was a symptom due to an underline disease, a disease code was used (e.g., fluid retention due to heart problem coded as I51.9 Heart disease, unspecified; fluid retention due to liver problem coded as K76.9 Liver disease, unspecified).
There were participants who reported the use of a prescription medication but did not know why to take it or refused to report the reason for use. These were coded as 99999, don’t know, and 77777, refused, respectively. There were a number of reported reasons could not be converted to an appropriate ICD-10-CM code. These entries have been coded as 55555, unknown. A few rare diseases were also coded as 55555, unknown.
RXDRSD1-- RXDRSD3: ICD-10-CM code description
Each ICD-10-CM code is associated with a description (diseases, symptoms, health status, and so on). RXDRSD1 is missing for unknown reasons (55555), refused (77777), or don’t know (99999) RXDRSC1 entries.
There are two files related to the prescription drug data. The contents of each file are described below. The files can be linked by the variable RXDDRGID.
The file named RXQ_RX_H contains data on all survey participants and their use of a prescription drug. Participants who reported the use of multiple prescription drugs will have multiple records, that is, a record for each drug.
The file named RXQ_DRUG contains therapeutic drug class information on all drugs reported by NHANES participants from 1988–1994 through 2013–2014. It contains drug (up to 4) and ingredient (up to 6) therapeutic category codes for each drug. It also has a variable that identifies if the drug is made up of a single or multiple ingredients.
RXQ_RX_H: Participant’s Use of Prescription Drug(s)
| Variable Name | Label |
|---|---|
| SEQN | Respondent sequence number |
| RXDUSE | Taken prescription medicine, past month |
| RXDDRUG | Generic drug name |
| RXDDRGID | Generic drug code |
| RXQSEEN | Medicine container seen by interviewer |
| RXDDAYS | Number of days taken medicine |
| RXDRSC1 | ICD-10-CM code 1 |
| RXDRSC2 | ICD-10-CM code 2 |
| RXDRSC3 | ICD-10-CM code 3 |
| RXDRSD1 | ICD-10-CM code 1 description |
| RXDRSD2 | ICD-10-CM code 2 description |
| RXDRSD3 | ICD-10-CM code 3 description |
| RXDCOUNT | Number of prescription medicines taken |
RXQ_DRUG: Drug Information
| Variable Name | Label |
|---|---|
| RXDDRGID | Generic drug code |
| RXDDRUG | Generic drug name |
| RXDINGFL | SINGLE/MULTIPLE INGREDIENT DRUG |
| RXDDCI1A | DRUG CATEGORY ID - CAT 1, LEV 1 |
| RXDDCI1B | DRUG CATEGORY ID - CAT 1, LEV 2 |
| RXDDCI1C | DRUG CATEGORY ID - CAT 1, LEV 3 |
| RXDDCI2A | DRUG CATEGORY ID - CAT 2, LEV1 |
| RXDDCI2B | DRUG CATEGORY ID - CAT 2, LEV 2 |
| RXDDCI2C | DRUG CATEGORY ID - CAT 2, LEV 3 |
| RXDDCI3A | DRUG CATEGORY ID - CAT 3, LEV 1 |
| RXDDCI3B | DRUG CATEGORY ID - CAT 3, LEV 2 |
| RXDDCI3C | DRUG CATEGORY ID - CAT 3, LEV 3 |
| RXDDCI4A | DRUG CATEGORY ID - CAT 4, LEV 1 |
| RXDDCI4B | DRUG CATEGORY ID - CAT 4, LEV 2 |
| RXDDCI4C | DRUG CATEGORY ID - CAT 4, LEV 3 |
| RXDDCN1A | DRUG CATEGORY NAME - CAT 1, LEV 1 |
| RXDDCN1B | DRUG CATEGORY NAME - CAT 1, LEV 2 |
| RXDDCN1C | DRUG CATEGORY NAME - CAT 1, LEV 3 |
| RXDDCN2A | DRUG CATEGORY NAME - CAT 2, LEV 1 |
| RXDDCN2B | DRUG CATEGORY NAME - CAT 2, LEV 2 |
| RXDDCN2C | DRUG CATEGORY NAME - CAT 2, LEV 3 |
| RXDDCN3A | DRUG CATEGORY NAME - CAT 3, LEV 1 |
| RXDDCN3B | DRUG CATEGORY NAME - CAT 3, LEV 2 |
| RXDDCN3C | DRUG CATEGORY NAME - CAT 3, LEV 3 |
| RXDDCN4A | DRUG CATEGORY NAME - CAT 4, LEV 1 |
| RXDDCN4B | DRUG CATEGORY NAME - CAT 4, LEV 2 |
| RXDDCN4C | DRUG CATEGORY NAME - CAT 4, LEV 3 |
| RXDICI1A | INGREDIENT CATEGORY ID - CAT 1, LEV 1 |
| RXDICI1B | INGREDIENT CATEGORY ID - CAT 1, LEV 2 |
| RXDICI1C | INGREDIENT CATEGORY ID - CAT 1, LEV 3 |
| RXDICI2A | INGREDIENT CATEGORY ID - CAT 2, LEV 1 |
| RXDICI2B | INGREDIENT CATEGORY ID - CAT 2, LEV 2 |
| RXDICI2C | INGREDIENT CATEGORY ID - CAT 2, LEV 3 |
| RXDICI3A | INGREDIENT CATEGORY ID - CAT 3, LEV 1 |
| RXDICI3B | INGREDIENT CATEGORY ID - CAT 3, LEV 2 |
| RXDICI3C | INGREDIENT CATEGORY ID - CAT 3, LEV 3 |
| RXDICI4A | INGREDIENT CATEGORY ID - CAT 4, LEV 1 |
| RXDICI4B | INGREDIENT CATEGORY ID - CAT 4, LEV 2 |
| RXDICI4C | INGREDIENT CATEGORY ID - CAT 4, LEV 3 |
| RXDICI5A | INGREDIENT CATEGORY ID - CAT 5, LEV 1 |
| RXDICI5B | INGREDIENT CATEGORY ID - CAT 5, LEV 2 |
| RXDICI5C | INGREDIENT CATEGORY ID - CAT 5, LEV 3 |
| RXDICI6A | INGREDIENT CATEGORY ID - CAT 6, LEV 1 |
| RXDICI6B | INGREDIENT CATEGORY ID - CAT 6, LEV 2 |
| RXDICI6C | INGREDIENT CATEGORY ID - CAT 6, LEV 3 |
| RXDICN1A | INGREDIENT CATEGORY NAME - CAT 1, LEV 1 |
| RXDICN1B | INGREDIENT CATEGORY NAME - CAT 1, LEV 2 |
| RXDICN1C | INGREDIENT CATEGORY NAME - CAT 1, LEV 3 |
| RXDICN2A | INGREDIENT CATEGORY NAME - CAT 2, LEV 1 |
| RXDICN2B | INGREDIENT CATEGORY NAME - CAT 2, LEV 2 |
| RXDICN2C | INGREDIENT CATEGORY NAME - CAT 2, LEV 3 |
| RXDICN3A | INGREDIENT CATEGORY NAME - CAT 3, LEV 1 |
| RXDICN3B | INGREDIENT CATEGORY NAME - CAT 3, LEV 2 |
| RXDICN3C | INGREDIENT CATEGORY NAME - CAT 3, LEV 3 |
| RXDICN4A | INGREDIENT CATEGORY NAME - CAT 4, LEV 1 |
| RXDICN4B | INGREDIENT CATEGORY NAME - CAT 4, LEV 2 |
| RXDICN4C | INGREDIENT CATEGORY NAME - CAT 4, LEV 3 |
| RXDICN5A | INGREDIENT CATEGORY NAME - CAT 5, LEV 1 |
| RXDICN5B | INGREDIENT CATEGORY NAME - CAT 5, LEV 2 |
| RXDICN5C | INGREDIENT CATEGORY NAME - CAT 5, LEV 3 |
| RXDICN6A | INGREDIENT CATEGORY NAME - CAT 6, LEV 1 |
| RXDICN6B | INGREDIENT CATEGORY NAME - CAT 6, LEV 2 |
| RXDICN6C | INGREDIENT CATEGORY NAME - CAT 6, LEV 3 |
The variable RXDCOUNT provides a count of all prescription products reported in the prescription medication section adjusting for products moved into or out of the final file. The count includes products reported as “refused” or “don’t know” by participants who reported they had taken a prescription medication but did not know the name of the medication or refused to report the name of the medication. Drugs released as “unknown drug” are also included in the count. However, prescription supplements in the Dietary Supplements File are not included in the total count. Therefore, this variable does not provide a comprehensive count of all prescription products used by the survey participant.
In some cases, it may appear as though participants reported the same prescription drug more than once. That is, the same generic ingredient name and product code may be listed more than once. There are a several reasons for these duplications. Participants may have reported different brand name medications which had the same generic ingredient name (e.g., “Oxycontin” vs. “Roxicodone”), the medications may have been different forms or dosages of the same product (e.g., Albuterol “oral tablet” vs. “inhalation solution”, or Furosemide “20 mg” vs. “40 mg”), or participants may have reported different lengths of use or reasons for use of the products.
The health problem as the main reason for taking medication was self-reported. The released variables, ICD-10-CM codes/description, were used to classify the health problems related to the medication use, and should not be considered as diagnoses from physicians.
During the data editing process, outlier values were examined. When there was insufficient information to conclude that values were invalid, they were left in the data set. Analysts should examine the distribution of the data and consider whether or not it is appropriate to include or exclude extreme values in a given analysis.
Respondent sequence number (SEQN) in the prescription medication data is not a unique identifier. Participants who reported the use of multiple prescription drugs will have multiple records, that is, a record for each drug. Analysts should convert a drug-level data to a person-level data, that is, a record for each person, before merging it with NHANES demographic and other data files by using SEQN.
Please refer to the NHANES Analytic Guidelines and the on-line NHANES Tutorial for further details on the use of sample weights and other analytic issues.
| Code or Value | Value Description | Count | Cumulative | Skip to Item |
|---|---|---|---|---|
| 1 | Yes | 14100 | 14100 | |
| 2 | No | 6089 | 20189 | End of Section |
| 7 | Refused | 4 | 20193 | End of Section |
| 9 | Don't know | 1 | 20194 | End of Section |
| . | Missing | 0 | 20194 |
| Code or Value | Value Description | Count | Cumulative | Skip to Item |
|---|---|---|---|---|
| Generic drug name | Value was recorded | 14016 | 14016 | |
| 55555 | Unknown | 6 | 14022 | |
| 77777 | Refused | 16 | 14038 | |
| 99999 | Don't know | 62 | 14100 | |
| < blank > | Missing | 6094 | 20194 |
| Code or Value | Value Description | Count | Cumulative | Skip to Item |
|---|---|---|---|---|
| Generic drug code | Value was recorded | 14016 | 14016 | |
| < blank > | Missing | 6178 | 20194 |
| Code or Value | Value Description | Count | Cumulative | Skip to Item |
|---|---|---|---|---|
| 1 | Yes | 12477 | 12477 | |
| 2 | No | 767 | 13244 | |
| 3 | Only pharmacy print out seen | 775 | 14019 | |
| . | Missing | 6175 | 20194 |
| Code or Value | Value Description | Count | Cumulative | Skip to Item |
|---|---|---|---|---|
| 1 to 25550 | Range of Values | 13740 | 13740 | |
| 77777 | Refused | 0 | 13740 | |
| 99999 | Don't know | 278 | 14018 | |
| . | Missing | 6176 | 20194 |
| Code or Value | Value Description | Count | Cumulative | Skip to Item |
|---|---|---|---|---|
| ICD-10-CM code 1 | Value was recorded | 13633 | 13633 | |
| 55555 | Unknown | 41 | 13674 | |
| 77777 | Refused | 8 | 13682 | |
| 99999 | Don't know | 340 | 14022 | |
| < blank > | Missing | 6172 | 20194 |
| Code or Value | Value Description | Count | Cumulative | Skip to Item |
|---|---|---|---|---|
| ICD-10-CM code 2 | Value was recorded | 714 | 714 | |
| < blank > | Missing | 19480 | 20194 |
| Code or Value | Value Description | Count | Cumulative | Skip to Item |
|---|---|---|---|---|
| ICD-10-CM code 3 | Value was recorded | 127 | 127 | |
| < blank > | Missing | 20067 | 20194 |
| Code or Value | Value Description | Count | Cumulative | Skip to Item |
|---|---|---|---|---|
| ICD-10-CM code 1 description | Value was recorded | 13633 | 13633 | |
| < blank > | Missing | 6561 | 20194 |
| Code or Value | Value Description | Count | Cumulative | Skip to Item |
|---|---|---|---|---|
| ICD-10-CM code 2 description | Value was recorded | 714 | 714 | |
| < blank > | Missing | 19480 | 20194 |
| Code or Value | Value Description | Count | Cumulative | Skip to Item |
|---|---|---|---|---|
| ICD-10-CM code 3 description | Value was recorded | 127 | 127 | |
| < blank > | Missing | 20067 | 20194 |
| Code or Value | Value Description | Count | Cumulative | Skip to Item |
|---|---|---|---|---|
| 1 to 23 | Range of Values | 14100 | 14100 | |
| . | Missing | 6094 | 20194 |
| ICD-10-CM code | Description |
|---|---|
| A08.4 | Viral intestinal infection, unspecified |
| A09 | Infectious gastroenteritis and colitis, unspecified |
| A15 | Respiratory tuberculosis |
| A15.P | Prevent tuberculosis |
| A41.9 | Sepsis, unspecified organism |
| A44.9 | Bartonellosis, unspecified |
| A49.02 | Methicillin resistant Staphylococcus aureus infection, unspecified site |
| A49.9 | Bacterial infection, unspecified |
| A49.9P | Prevent bacterial infection |
| A60.9 | Anogenital herpesviral infection, unspecified |
| A69.2 | Lyme disease |
| B00.1 | Herpesviral vesicular dermatitis |
| B00.9 | Herpesviral infection, unspecified |
| B02 | Zoster [herpes zoster] |
| B07 | Viral warts |
| B18.2 | Chronic viral hepatitis C |
| B19.1 | Unspecified viral hepatitis B |
| B20 | Human immunodeficiency virus [HIV] disease |
| B34.9 | Viral infection, unspecified |
| B35.1 | Tinea unguium |
| B35.3 | Tinea pedis |
| B35.4 | Tinea corporis |
| B35.9 | Dermatophytosis, unspecified |
| B37.0 | Candidal stomatitis |
| B37.3 | Candidiasis of vulva and vagina |
| B37.9 | Candidiasis, unspecified |
| B86 | Scabies |
| B96.81 | Helicobacter pylori [H. pylori] as the cause of diseases classified elsewhere |
| B97.4 | Respiratory syncytial virus as the cause of diseases classified elsewhere |
| C18 | Malignant neoplasm of colon |
| C41.9 | Malignant neoplasm of bone and articular cartilage, unspecified |
| C44 | Other and unspecified malignant neoplasm of skin |
| C50 | Malignant neoplasm of breast |
| C50.P | Prevent barest cancer |
| C54.P | Prevent uterine cancer |
| C61 | Malignant neoplasm of prostate |
| C73 | Malignant neoplasm of thyroid gland |
| C74 | Malignant neoplasm of adrenal gland |
| C80.1 | Malignant (primary) neoplasm, unspecified |
| C95.9 | Leukemia, unspecified |
| D25.P | Prevent uterine fibroids |
| D35.2 | Benign neoplasm of pituitary gland |
| D49 | Neoplasms of unspecified behavior |
| D50.9 | Iron deficiency anemia, unspecified |
| D64.9 | Anemia, unspecified |
| D75.9P | Prevent blood clots |
| D89.9 | Disorder involving the immune mechanism, unspecified |
| E03.9 | Hypothyroidism, unspecified |
| E04.1 | Nontoxic single thyroid nodule |
| E04.9 | Nontoxic goiter, unspecified |
| E05.9 | Thyrotoxicosis, unspecified |
| E06.3 | Autoimmune thyroiditis |
| E06.9 | Thyroiditis, unspecified |
| E07.9 | Disorder of thyroid, unspecified |
| E10 | Type 1 diabetes mellitus |
| E10.2 | Type 1 diabetes mellitus with kidney complications |
| E11 | Type 2 diabetes mellitus |
| E11.2 | Type 2 diabetes mellitus with kidney complications |
| E11.2P | Prevent diabetic kidney disease |
| E11.4 | Type 2 diabetes mellitus with neurological complications |
| E11.P | Prevent diabetes |
| E21.3 | Hyperparathyroidism, unspecified |
| E26.9 | Hyperaldosteronism, unspecified |
| E27.1 | Primary adrenocortical insufficiency |
| E27.40 | Unspecified adrenocortical insufficiency |
| E27.9 | Disorder of adrenal gland, unspecified |
| E28.2 | Polycystic ovarian syndrome |
| E28.31 | Premature menopause |
| E28.9 | Ovarian dysfunction, unspecified |
| E29.1 | Testicular hypofunction |
| E34.3 | Short stature due to endocrine disorder |
| E34.9 | Endocrine disorder, unspecified |
| E53.9 | Vitamin B deficiency, unspecified |
| E56.9 | Vitamin deficiency, unspecified |
| E56.9P | Prevent vitamin deficiency |
| E58 | Dietary calcium deficiency |
| E63.9 | Nutritional deficiency, unspecified |
| E66 | Overweight and obesity |
| E66.3 | Overweight |
| E66.9 | Obesity, unspecified |
| E78.0 | Pure hypercholesterolemia |
| E78.0P | Prevent high cholesterol |
| E78.1 | Pure hyperglyceridemia |
| E79.0 | Hyperuricemia without signs of inflammatory arthritis and tophaceous disease |
| E83.3 | Disorders of phosphorus metabolism and phosphatases |
| E83.52 | Hypercalcemia |
| E87.1 | Hypo-osmolality and hyponatremia |
| E87.6 | Hypokalemia |
| E87.6P | Prevent hypokalemia |
| E87.7 | Fluid overload |
| E87.8 | Other disorders of electrolyte and fluid balance, not elsewhere classified |
| E88.81 | Metabolic syndrome |
| F11.2 | Opioid dependence |
| F11.23 | Opioid dependence with withdrawal |
| F17.203 | Nicotine dependence unspecified, with withdrawal |
| F20 | Schizophrenia |
| F29 | Unspecified psychosis not due to a substance or known physiological condition |
| F30 | Manic episode |
| F31.9 | Bipolar disorder, unspecified |
| F32.9 | Major depressive disorder, single episode, unspecified |
| F39 | Unspecified mood [affective] disorder |
| F41.0 | Panic disorder [episodic paroxysmal anxiety] without agoraphobia |
| F41.9 | Anxiety disorder, unspecified |
| F42 | Obsessive-compulsive disorder |
| F43.1 | Post-traumatic stress disorder (PTSD) |
| F43.9 | Reaction to severe stress, unspecified |
| F50.9 | Eating disorder, unspecified |
| F60.0 | Paranoid personality disorder |
| F84.0 | Autistic disorder |
| F90 | Attention-deficit hyperactivity disorders |
| F91.3 | Oppositional defiant disorder |
| F91.9 | Conduct disorder, unspecified |
| F95.2 | Tourette's disorder |
| F95.9 | Tic disorder, unspecified |
| F98.0 | Enuresis not due to a substance or known physiological condition |
| F98.4 | Stereotyped movement disorders |
| F99 | Mental disorder, not otherwise specified |
| G20 | Parkinson's disease |
| G25.0 | Essential tremor |
| G25.81 | Restless legs syndrome |
| G30.9 | Alzheimer's disease, unspecified |
| G31.84 | Mild cognitive impairment, so stated |
| G31.9 | Degenerative disease of nervous system, unspecified |
| G35 | Multiple sclerosis |
| G40 | Epilepsy and recurrent seizures |
| G43 | Migraine |
| G43.P | Prevent migraine |
| G45.9 | Transient cerebral ischemic attack, unspecified |
| G47.0 | Insomnia |
| G47.30 | Sleep apnea, unspecified |
| G47.41 | Narcolepsy |
| G47.9 | Sleep disorder, unspecified |
| G50.0 | Trigeminal neuralgia |
| G56.0 | Carpal tunnel syndrome |
| G81.1 | Spastic hemiplegia |
| G83.9 | Paralytic syndrome, unspecified |
| G89.18 | Other acute postprocedural pain |
| G89.3 | Neoplasm related pain (acute) (chronic) |
| G89.4 | Chronic pain syndrome |
| H00.0 | Hordeolum (externum) (internum) of eyelid |
| H00.1 | Chalazion |
| H02.84 | Edema of eyelid |
| H04.12 | Dry eye syndrome |
| H10 | Conjunctivitis |
| H10.1 | Acute atopic conjunctivitis |
| H10.P | Prevent eye infection |
| H11.3 | Conjunctival hemorrhage |
| H26.9 | Unspecified cataract |
| H33 | Retinal detachments and breaks |
| H35.30 | Unspecified macular degeneration (age-related) |
| H40 | Glaucoma |
| H40.P | Prevent glaucoma |
| H57.8 | Other specified disorders of eye and adnexa |
| H57.9 | Unspecified disorder of eye and adnexa |
| H60.9 | Unspecified otitis externa |
| H61.2P | Prevent ear wax |
| H66.9 | Otitis media, unspecified |
| H66.9P | Prevent ear infection |
| H81.0 | Ménière's disease |
| H81.1 | Benign paroxysmal vertigo |
| H81.9 | Unspecified disorder of vestibular function |
| H92.0 | Otalgia |
| H93.9 | Unspecified disorder of ear |
| I10 | Essential (primary) hypertension |
| I10.P | Prevent hypertension |
| I20.9 | Angina pectoris, unspecified |
| I21 | ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction |
| I21.P | Prevent heart attack/myocardial infarction |
| I26 | Pulmonary embolism |
| I38 | Endocarditis, valve unspecified |
| I42.9 | Cardiomyopathy, unspecified |
| I47.1 | Supraventricular tachycardia |
| I48.91 | Unspecified atrial fibrillation |
| I48.92 | Unspecified atrial flutter |
| I49.1 | Atrial premature depolarization |
| I49.9 | Cardiac arrhythmia, unspecified |
| I50.9 | Heart failure, unspecified |
| I51.7 | Cardiomegaly |
| I51.9 | Heart disease, unspecified |
| I51.9P | Prevent heart disease |
| I63 | Cerebral infarction |
| I63.P | Prevent stroke |
| I70.2 | Atherosclerosis of native arteries of extremities |
| I70.21 | Atherosclerosis of native arteries of extremities with intermittent claudication |
| I72.9P | Prevent aneurysm |
| I73.0 | Raynaud's syndrome |
| I77.9 | Disorder of arteries and arterioles, unspecified |
| I80.3 | Phlebitis and thrombophlebitis of lower extremities, unspecified |
| I95.9 | Hypotension, unspecified |
| I99.9 | Unspecified disorder of circulatory system |
| J00 | Acute nasopharyngitis [common cold] |
| J01 | Acute sinusitis |
| J01.9 | Acute sinusitis, unspecified |
| J02 | Acute pharyngitis |
| J02.0P | Prevent strep throat |
| J03 | Acute tonsillitis |
| J06.9 | Acute upper respiratory infection, unspecified |
| J09 | Influenza due to certain identified influenza viruses |
| J18.9 | Pneumonia, unspecified organism |
| J20.9 | Acute bronchitis, unspecified |
| J30.1 | Allergic rhinitis due to pollen |
| J30.2 | Other seasonal allergic rhinitis |
| J30.9 | Allergic rhinitis, unspecified |
| J32.9 | Chronic sinusitis, unspecified |
| J33.9 | Nasal polyp, unspecified |
| J40 | Bronchitis, not specified as acute or chronic |
| J42 | Unspecified chronic bronchitis |
| J43 | Emphysema |
| J44.9 | Chronic obstructive pulmonary disease, unspecified |
| J45 | Asthma |
| J45.P | Prevent asthma |
| J81 | Pulmonary edema |
| J84.10 | Pulmonary fibrosis, unspecified |
| J98.4 | Other disorders of lung |
| J98.9 | Respiratory disorder, unspecified |
| K02.7 | Dental root caries |
| K02.P | Prevent tooth decay |
| K04.7 | Periapical abscess without sinus |
| K04.7P | Prevent tooth infection |
| K05.6 | Periodontal disease, unspecified |
| K08.4 | Partial loss of teeth |
| K08.8 | Other specified disorders of teeth and supporting structures |
| K11.7 | Disturbances of salivary secretion |
| K12.0 | Recurrent oral aphthae |
| K12.2 | Cellulitis and abscess of mouth |
| K13.79 | Other lesions of oral mucosa |
| K21 | Gastro-esophageal reflux disease |
| K21.P | Prevent acid reflux |
| K22.1 | Ulcer of esophagus |
| K25 | Gastric ulcer |
| K25.P | Prevent gastric ulcer |
| K27 | Peptic ulcer, site unspecified |
| K29.70 | Gastritis, unspecified, without bleeding |
| K30 | Functional dyspepsia |
| K31.4 | Gastric diverticulum |
| K31.84 | Gastroparesis |
| K31.9 | Disease of stomach and duodenum, unspecified |
| K31.9P | Prevent stomach problem |
| K44 | Diaphragmatic hernia |
| K46 | Unspecified abdominal hernia |
| K50 | Crohn's disease [regional enteritis] |
| K51 | Ulcerative colitis |
| K52.9 | Noninfective gastroenteritis and colitis, unspecified |
| K56.60 | Unspecified intestinal obstruction |
| K57 | Diverticular disease of intestine |
| K58 | Irritable bowel syndrome |
| K59.0 | Constipation |
| K59.9 | Functional intestinal disorder, unspecified |
| K64 | Hemorrhoids and perianal venous thrombosis |
| K64.P | Prevent hemorrhoids |
| K72.9 | Hepatic failure, unspecified |
| K74.5 | Biliary cirrhosis, unspecified |
| K76.0 | Fatty (change of) liver, not elsewhere classified |
| K76.9 | Liver disease, unspecified |
| K82.9 | Disease of gallbladder, unspecified |
| K83.1 | Obstruction of bile duct |
| K86.8 | Other specified diseases of pancreas |
| K86.9 | Disease of pancreas, unspecified |
| K91.2 | Postsurgical malabsorption, not elsewhere classified |
| K91.5 | Postcholecystectomy syndrome |
| K92.2 | Gastrointestinal hemorrhage, unspecified |
| K92.9 | Disease of digestive system, unspecified |
| L01.0 | Impetigo |
| L02.92 | Furuncle, unspecified |
| L03.90 | Cellulitis, unspecified |
| L08.9 | Local infection of the skin and subcutaneous tissue, unspecified |
| L20.9 | Atopic dermatitis, unspecified |
| L22 | Diaper dermatitis |
| L23 | Allergic contact dermatitis |
| L23.7 | Allergic contact dermatitis due to plants, except food |
| L29.9 | Pruritus, unspecified |
| L30.9 | Dermatitis, unspecified |
| L40 | Psoriasis |
| L40.5 | Arthropathic psoriasis |
| L50 | Urticaria |
| L55 | Sunburn |
| L57.8 | Other skin changes due to chronic exposure to nonionizing radiation |
| L64 | Androgenic alopecia |
| L70 | Acne |
| L71 | Rosacea |
| L73.0 | Acne keloid |
| L73.9 | Follicular disorder, unspecified |
| L81.9 | Disorder of pigmentation, unspecified |
| L85.3 | Xerosis cutis |
| L93 | Lupus erythematosus |
| L97 | Non-pressure chronic ulcer of lower limb, not elsewhere classified |
| L98.9 | Disorder of the skin and subcutaneous tissue, unspecified |
| M06.9 | Rheumatoid arthritis, unspecified |
| M10.9 | Gout, unspecified |
| M13 | Other arthritis |
| M19.9 | Osteoarthritis, unspecified site |
| M19.90 | Unspecified osteoarthritis, unspecified site |
| M1A | Chronic gout |
| M25.5 | Pain in joint |
| M25.51 | Pain in shoulder |
| M25.52 | Pain in elbow |
| M25.53 | Pain in wrist |
| M25.55 | Pain in hip |
| M25.56 | Pain in knee |
| M27.2 | Inflammatory conditions of jaws |
| M31.6 | Other giant cell arteritis |
| M35.0 | Sicca syndrome [Sjögren] |
| M35.3 | Polymyalgia rheumatica |
| M43.9 | Deforming dorsopathy, unspecified |
| M45 | Ankylosing spondylitis |
| M48.0 | Spinal stenosis |
| M51.9 | Unspecified thoracic, thoracolumbar and lumbosacral intervertebral disc disorder |
| M54.2 | Cervicalgia |
| M54.5 | Low back pain |
| M54.9 | Dorsalgia, unspecified |
| M60.9 | Myositis, unspecified |
| M62.81 | Muscle weakness (generalized) |
| M62.83 | Muscle spasm |
| M75.1 | Rotator cuff tear or rupture, not specified as traumatic |
| M79.1 | Myalgia |
| M79.2 | Neuralgia and neuritis, unspecified |
| M79.603 | Pain in arm, unspecified |
| M79.606 | Pain in leg, unspecified |
| M79.64 | Pain in hand and fingers |
| M79.646 | Pain in finger |
| M79.673 | Pain in unspecified foot |
| M79.7 | Fibromyalgia |
| M81 | Osteoporosis without current pathological fracture |
| M81.P | Prevent bone loss/osteoporosis |
| M85.80 | Other specified disorders of bone density and structure, unspecified site |
| M87.9 | Osteonecrosis, unspecified |
| M88 | Osteitis deformans [Paget's disease of bone] |
| M94.0 | Chondrocostal junction syndrome |
| M94.26 | Chondromalacia, knee |
| N12 | Tubulo-interstitial nephritis, not specified as acute or chronic |
| N18.9 | Chronic kidney disease, unspecified |
| N19 | Unspecified kidney failure |
| N20.0 | Calculus of kidney |
| N20.0P | Prevent kidney stone |
| N23 | Unspecified renal colic |
| N28.9 | Disorder of kidney and ureter, unspecified |
| N28.9P | Prevent kidney disease |
| N30 | Cystitis |
| N30.1 | Interstitial cystitis (chronic) |
| N31.9 | Neuromuscular dysfunction of bladder, unspecified |
| N32.81 | Overactive bladder |
| N32.9 | Bladder disorder, unspecified |
| N34.1 | Nonspecific urethritis |
| N39.0 | Urinary tract infection, site not specified |
| N39.0P | Prevent urinary tract infection |
| N39.4 | Other specified urinary incontinence |
| N39.9 | Disorder of urinary system, unspecified |
| N40 | Enlarged prostate |
| N41.0 | Acute prostatitis |
| N42.9 | Disorder of prostate, unspecified |
| N48.29 | Other inflammatory disorders of penis |
| N48.89 | Other specified disorders of penis |
| N52.9 | Male erectile dysfunction, unspecified |
| N61 | Inflammatory disorders of breast |
| N73.9 | Female pelvic inflammatory disease, unspecified |
| N76.0 | Acute vaginitis |
| N80.9 | Endometriosis, unspecified |
| N81.4 | Uterovaginal prolapse, unspecified |
| N83.2 | Other and unspecified ovarian cysts |
| N85.0 | Endometrial hyperplasia |
| N91.0 | Primary amenorrhea |
| N92 | Excessive, frequent and irregular menstruation |
| N92.6 | Irregular menstruation, unspecified |
| N93.9 | Abnormal uterine and vaginal bleeding, unspecified |
| N94.3 | Premenstrual tension syndrome |
| N94.6 | Dysmenorrhea, unspecified |
| N95.1 | Menopausal and female climacteric states |
| N95.1P | Prevent menopause symptoms |
| N95.2 | Postmenopausal atrophic vaginitis |
| N97.9 | Female infertility, unspecified |
| O12.0 | Gestational edema |
| O13.9 | Gestational [pregnancy-induced] hypertension without significant proteinuria, unspecified trimester |
| O24.4 | Gestational diabetes mellitus |
| Q99.9 | Chromosomal abnormality, unspecified |
| R00.0 | Tachycardia, unspecified |
| R00.0P | Prevent tachycardia |
| R00.2 | Palpitations |
| R00.9 | Unspecified abnormalities of heart beat |
| R01.1 | Cardiac murmur, unspecified |
| R03.0 | Elevated blood-pressure reading, without diagnosis of hypertension |
| R05 | Cough |
| R06.02 | Shortness of breath |
| R06.2 | Wheezing |
| R06.6 | Hiccough |
| R06.9 | Unspecified abnormalities of breathing |
| R07.89 | Other chest pain |
| R07.9 | Chest pain, unspecified |
| R07.9P | Prevent chest pain |
| R09.3 | Abnormal sputum |
| R09.81 | Nasal congestion |
| R09.82 | Postnasal drip |
| R09.89 | Other specified symptoms and signs involving the circulatory and respiratory systems |
| R10.83 | Colic |
| R10.9 | Unspecified abdominal pain |
| R11 | Nausea and vomiting |
| R11.0 | Nausea |
| R11.1 | Vomiting |
| R11.1P | Prevent vomiting |
| R11.P | Prevent nausea or vomiting |
| R12 | Heartburn |
| R14.0 | Abdominal distension (gaseous) |
| R15 | Fecal incontinence |
| R19.7 | Diarrhea, unspecified |
| R20.0 | Anesthesia of skin |
| R20.2 | Paresthesia of skin |
| R21 | Rash and other nonspecific skin eruption |
| R25.1 | Tremor, unspecified |
| R25.2 | Cramp and spasm |
| R25.2P | Prevent cramp and spasm |
| R29.90 | Unspecified symptoms and signs involving the nervous system |
| R30 | Pain associated with micturition |
| R32 | Unspecified urinary incontinence |
| R33.9 | Retention of urine, unspecified |
| R35.0 | Frequency of micturition |
| R35.1 | Nocturia |
| R39.11 | Hesitancy of micturition |
| R39.12 | Poor urinary stream |
| R39.15 | Urgency of urination |
| R39.9 | Unspecified symptoms and signs involving the genitourinary system |
| R41.3 | Other amnesia |
| R41.840 | Attention and concentration deficit |
| R42 | Dizziness and giddiness |
| R44.0 | Auditory hallucinations |
| R45.0 | Nervousness |
| R45.1 | Restlessness and agitation |
| R45.4 | Irritability and anger |
| R45.86 | Emotional lability |
| R46.4 | Slowness and poor responsiveness |
| R50.9 | Fever, unspecified |
| R51 | Headache |
| R51.P | Prevent headache |
| R52 | Pain, unspecified |
| R53.83 | Other fatigue |
| R56.9 | Unspecified convulsions |
| R59.0 | Localized enlarged lymph nodes |
| R59.9 | Enlarged lymph nodes, unspecified |
| R60.9 | Edema, unspecified |
| R63.0 | Anorexia |
| R63.4 | Abnormal weight loss |
| R68.2 | Dry mouth, unspecified |
| R68.84 | Jaw pain |
| R73 | Elevated blood glucose level |
| R73.9 | Hyperglycemia, unspecified |
| R80.9 | Proteinuria, unspecified |
| R91 | Abnormal findings on diagnostic imaging of lung |
| R94.5 | Abnormal results of liver function studies |
| S05 | Injury of eye and orbit |
| S22 | Fracture of rib(s), sternum and thoracic spine |
| S62.6 | Fracture of other and unspecified finger(s) |
| S76.9 | Injury of unspecified muscles, fascia and tendons at thigh level |
| S81.80 | Unspecified open wound of lower leg |
| S82.0 | Fracture of patella |
| S97.8 | Crushing injury of foot |
| T14.9 | Unspecified injury |
| T30.0 | Burn of unspecified body region, unspecified degree |
| T63.4 | Toxic effect of venom of other arthropods |
| T75.3 | Motion sickness |
| T78.40 | Allergy, unspecified |
| T86.9P | Prevent transplanted organ and tissue rejection |
| T88.7 | Unspecified adverse effect of drug or medicament |
| W54.0 | Bitten by dog |
| Z34.9 | Encounter for supervision of normal pregnancy, unspecified |
| Z47 | Orthopedic aftercare |
| Z48.29 | Encounter for aftercare following bone marrow transplant |
| Z48.810 | Encounter for surgical aftercare following surgery on the sense organs |
| Z51.11 | Encounter for antineoplastic chemotherapy |
| Z77.120 | Contact with and (suspected) exposure to mold (toxic) |
| Z79.02 | Long term (current) use of antithrombotics/antiplatelets |
| Z79.2 | Long term (current) use of antibiotics |
| Z79.3 | Long term (current) use of hormonal contraceptives |
| Z79.52 | Long term (current) use of systemic steroids |
| Z79.81 | Long term (current) use of agents affecting estrogen receptors and estrogen levels |
| Z79.P | Prophylactic medication |
| Z87.11 | Personal history of peptic ulcer disease |
| Z88 | Allergy status to drugs, medicaments and biological substances |
| Z90.5 | Acquired absence of kidney |
| Z90.710 | Acquired absence of both cervix and uterus |
| Z91.01 | Food allergy status |
| Z91.030 | Bee allergy status |
| Z99.2 | Dependence on renal dialysis |
| Z94.0 | Kidney transplant status |
| Z95.0 | Presence of cardiac pacemaker |
| Z95.1 | Presence of aortocoronary bypass graft |
| Z95.2 | Presence of prosthetic heart valve |
| Z95.5 | Presence of coronary angioplasty implant and graft |
| Z95.9 | Presence of cardiac and vascular implant and graft, unspecified |
| Z96.64 | Presence of artificial hip joint |
| Z96.65 | Presence of artificial knee joint |
| Z98.84 | Bariatric surgery status |